Summary

The Japan idiopathic pulmonary fibrosis treatment market size reached USD 181.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 345.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.4% during 2025-2033.

Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial pneumonia characterized by the thickening and scarring of lung tissue. The clinical symptoms of IPF include breathing difficulties, persistent dry cough, fatigue, loss of appetite, and swollen limbs. It is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs, which slows the rate at which the scar tissues are formed and controls the symptoms associated with the disease. Supportive therapeutic options, including pulmonary rehabilitation, palliative care, and supplemental oxygen therapy, are also provided as the effective treatment plan for IPF.

Japan Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the IPF treatment market growth across Japan. This can be attributed to a rise in the consumption of nicotine-based products, a surge in pollution levels, and rising stress levels. Other than this, increasing health consciousness and rising awareness regarding the effective prevention and management strategies of IPF are acting as growth-inducing factors. Other factors, such as extensive research and development (R&D) activities for introducing novel therapies, and advancements in the existing healthcare infrastructure, are positively influencing the market growth across the country.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the Japan idiopathic pulmonary fibrosis treatment market report, along with forecasts at the country and regional levels from 2025-2033. Our report has categorized the market based on drug class and end user.

Breakup by Drug Class:
• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors

Breakup by End User:
• Hospitals
• Long-term Care Facilities
• Others

Breakup by Region:
• Kanto Region
• Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.

Key Questions Answered in This Report:
• How has the Japan idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan idiopathic pulmonary fibrosis treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the drug class?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the Japan idiopathic pulmonary fibrosis treatment market and who are the key players?
• What is the degree of competition in the industry?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Japan Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 Kanto Region
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Kinki Region
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Central/ Chubu Region
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Kyushu-Okinawa Region
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Tohoku Region
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Chugoku Region
8.6.1 Market Trends
8.6.2 Market Forecast
8.7 Hokkaido Region
8.7.1 Market Trends
8.7.2 Market Forecast
8.8 Shikoku Region
8.8.1 Market Trends
8.8.2 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Policy and Regulatory Landscape
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players

ページTOPに戻る

List of Tables/Graphs

List of Figures
Figure 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019-2024
Figure 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %)
2024
Figure 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %)
2024
Figure 6: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %)
2024
Figure 7: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 8: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 9: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 10: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 11: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 12: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 13: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 14: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 15: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 16: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 17: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 18: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 19: Kanto Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 20: Kanto Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 21: Kinki Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 22: Kinki Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 23: Central/ Chubu Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 24: Central/ Chubu Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 25: Kyushu-Okinawa Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 26: Kyushu-Okinawa Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 27: Tohoku Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 28: Tohoku Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 29: Chugoku Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 30: Chugoku Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 31: Hokkaido Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 32: Hokkaido Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 33: Shikoku Region: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD​​​)
2019 & 2024
Figure 34: Shikoku Region: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD​​​)
2025-2033
Figure 35: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 36: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 37: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights
2024 and 2033
Table 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million USD​​​)
2025-2033
Table 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million USD​​​)
2025-2033
Table 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million USD​​​)
2025-2033
Table 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
Table 6: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players